Immune Mechanisms in Bacillus Calmette-Guerin Immunotherapy for Superficial Bladder Cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
Morales, 1976, Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors, J Urol, 116, 180, 10.1016/S0022-5347(17)58737-6
Ratliff, 1991, Strategy for improving therapy of superficial bladder cancer, World J Urol, 9, 95, 10.1007/BF00184040
Chapman, 1993, Non-antibody immunotherapy of cancer, Curr Opin Immunol, 5, 726, 10.1016/0952-7915(93)90128-F
Lamm, 1991, A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder, N Engl J Med, 325, 1205, 10.1056/NEJM199110243251703
Lamm, 1995, Randomized intergroup comparison of bacillus Calmette-Guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder, Urol Oncol, 1, 119, 10.1016/1078-1439(95)00041-F
Malmström, 1999, 5-Year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma, J Urol, 161, 1124, 10.1016/S0022-5347(01)61607-0
Herr, 1988, Bacillus Calmette-Guerin therapy alters the progression of superficial bladder cancer, J Clin Oncol, 6, 1450, 10.1200/JCO.1988.6.9.1450
Herr, 1997, Surgical therapy of high-risk bladder carcinoma. Transurethral resection (TUR) alone vs adjuvant BCG, 45
Lamm, 2000, Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study, J Urol, 163, 1124, 10.1016/S0022-5347(05)67707-5
Sylvester, 2002, Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials, J Urol, 168, 1964, 10.1016/S0022-5347(05)64273-5
Mahairas, 1996, Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis, J Bacteriol, 178, 1274, 10.1128/jb.178.5.1274-1282.1996
Behr, 1999, Comparative genomics of BCG vaccines by whole-genome DNA microarray, Science, 284, 1520, 10.1126/science.284.5419.1520
Schamhart, 2000, Urinary cytokines reflecting the immunological response in the urinary bladder to biological response modifiers: their practical use, Eur Urol, 37, 16, 10.1159/000052388
Prescott, 1992, Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall, J Urol, 147, 1636, 10.1016/S0022-5347(17)37668-1
Lage, 1986, Histological parameters and pitfalls in the interpretation of bladder biopsies in bacillus Calmette-Guerin treatment of superficial bladder cancer, J Urol, 135, 916, 10.1016/S0022-5347(17)45922-2
de Boer, 1997, Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer, Urol Res, 25, 31, 10.1007/BF00941903
Thalmann, 1997, Interleukin-8 expression in the urine after bacillus Calmette-Guerin therapy: a potential prognostic factor of tumor recurrence and progression, J Urol, 158, 1340, 10.1016/S0022-5347(01)64210-1
Thalmann, 2000, Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin, J Urol, 164, 2129, 10.1016/S0022-5347(05)66983-2
Jackson, 1998, Prognosis of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer by immunological urinary measurements: statistically weighted syndromes analysis, J Urol, 159, 1054, 10.1016/S0022-5347(01)63835-7
Jackson, 1995, Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guerin (BCG) immunotherapy, Clin Exp Immunol, 99, 369, 10.1111/j.1365-2249.1995.tb05560.x
Prescott, 1990, Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy, J Urol, 144, 1248, 10.1016/S0022-5347(17)39713-6
Haaff, 1986, Detection of interleukin-2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG, J Urol, 136, 970, 10.1016/S0022-5347(17)45142-1
De Boer, 1992, Induction of urinary interleukin-1 (IL-1), IL-2, IL-6 and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guerin in superficial bladder cancer, Cancer Immunol Immunother, 34, 306, 10.1007/BF01741551
Bohle, 1990, Detection of urinary TNF, IL 1, and IL 2 after local BCG immunotherapy for bladder carcinoma, Cytokine, 2, 175, 10.1016/1043-4666(90)90013-J
Alexandroff, 1996, Production of IL-5, a classical TH2 cytokine, following bacillus Calmette-Guérin immunotherapy of bladder cancer, Int J Oncol, 9, 179
Poppas, 1998, Intravesical bacille Calmette-Guerin induces the antiangiogenic chemokine interferon-inducible protein 10, Urology, 52, 268, 10.1016/S0090-4295(98)00188-5
Chen, 2001, BCG potentiates human chemokine induction in vivo and in vitro, J Urol, 165, 114
Böhle, 1990, Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall, J Urol, 144, 53, 10.1016/S0022-5347(17)39365-5
de Boer, 1991, Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis, Urol Res, 19, 45, 10.1007/BF00294021
Jackson, 1994, Induction of ICAM 1 expression on bladder tumours by BCG immunotherapy, J Clin Pathol, 47, 309, 10.1136/jcp.47.4.309
Fleischmann, 1989, Urinary interleukins in patients receiving intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer, Cancer, 64, 1447, 10.1002/1097-0142(19891001)64:7<1447::AID-CNCR2820640715>3.0.CO;2-Y
de Reijke, 1996, Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value, J Urol, 155, 477, 10.1016/S0022-5347(01)66424-3
Kaempfer, 1996, Prediction of response to treatment in superficial bladder carcinoma through pattern of Interleukin-2 gene expression, J Clin Oncol, 14, 1778, 10.1200/JCO.1996.14.6.1778
Soloway, 1977, Intravesical and systemic chemotherapy of murine bladder cancer, Cancer Res, 37, 2918
Gunther, 1999, Optimizing syngeneic orthotopic murine bladder cancer (MB49), Cancer Res, 59, 2834
Ratliff, 1987, Intravesical Bacillus Calmette-Guerin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guerin, Cancer Res, 47, 1762
Zhao, 2000, Role of a bacillus Calmette-Guerin fibronectin attachment protein in BCG-induced antitumor activity, Int J Cancer, 86, 83, 10.1002/(SICI)1097-0215(20000401)86:1<83::AID-IJC13>3.0.CO;2-R
Kavoussi, 1990, Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement of the expression of an antitumor response, J Clin Invest, 85, 62, 10.1172/JCI114434
Ratliff, 1987, Requirement of a thymus dependent immune response for BCG-mediated antitumor activity, J Urol, 137, 155, 10.1016/S0022-5347(17)43909-7
Ratliff, 1993, T-cell subsets required for intravesical BCG immunotherapy for bladder cancer, J Urol, 150, 1018, 10.1016/S0022-5347(17)35678-1
Brandau, 2001, NK cells are essential for effective BCG immunotherapy, Int J Cancer, 92, 697, 10.1002/1097-0215(20010601)92:5<697::AID-IJC1245>3.0.CO;2-Z
McAveney, 1994, Induction of TH1- and TH2-associated cytokine mRNA in mouse bladder following intravesical growth of the murine bladder tumor MB49 and BCG immunotherapy, Cancer Immunol Immunother, 39, 401, 10.1007/BF01534428
Shin, 1995, Induction of tumour necrosis factor-alpha (TNF-alpha) mRNA in bladders and spleens of mice after intravesical administration of bacillus Calmette-Guerin, Clin Exp Immunol, 100, 26, 10.1111/j.1365-2249.1995.tb03599.x
Brandau, 2000, Role of IFN-gamma and IL-10 in immunotherapy of bladder cancer with Mycobacterium bovis BCG, Immunobiology, 203, 350
Hawkyard, 1992, The inhibitory effects of interferon gamma on the growth of bladder cancer cells, J Urol, 147, 1399, 10.1016/S0022-5347(17)37582-1
Thanhauser, 1993, Induction of bacillus Calmette-Guerin-activated killer cells from human peripheral blood mononuclear cells against human bladder carcinoma cell lines in vitro, Cancer Immunol Immunother, 37, 105, 10.1007/BF01517042
de Reijke, 1993, Cytokine production by the human bladder carcinoma cell line T24 in the presence of bacillus Calmette-Guerin (BCG), Urol Res, 21, 349, 10.1007/BF00296835
Esuvaranathan, 1995, Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy, J Urol, 154, 572, 10.1016/S0022-5347(01)67113-1
Pryor, 1995, Antiproliferative effects of bacillus Calmette-Guerin and Interferon alpha-2b on human bladder cancer cells in vitro, Cancer Immunol Immunother, 41, 309, 10.1007/BF01517219
Pryor, 1995, Bacillus Calmette-Guerin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing, Br J Cancer, 71, 801, 10.1038/bjc.1995.155
Mizutani, 1992, Effects of bacillus Calmette-Guerin on cytotoxic activities of peripheral blood lymphocytes against human T24 lined and freshly isolated autologous urinary bladder transitional carcinoma cells in patients with urinary bladder cancer, Cancer, 69, 537, 10.1002/1097-0142(19920115)69:2<537::AID-CNCR2820690242>3.0.CO;2-3
Thanhäuser, 1995, The induction of bacillus-Calmette-Guérin-activated killer cells requires the presence of monocytes and T-helper type-1 cells, Cancer Immunol Immunother, 40, 103, 10.1007/BF01520291
Brandau, 2001, Activation of natural killer cells by Bacillus Calmette-Guerin, Eur Urol, 39, 518, 10.1159/000052497
Brandau, 2000, Perforin-mediated lysis of tumor cells by Mycobacterium Bovis Bacillus Calmette-Guerin-activated killer cells, Clin Cancer Res, 6, 3729
Reiss, 1999, BCG-immunotherapy of superficial bladder cancer: BCG-induced activation of MNCs is regulated by cytokines, Eur Urol, 36, 476
O'Donnell, 1999, Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette-Guerin, J Immunol, 163, 4246, 10.4049/jimmunol.163.8.4246
Mendez-Samperio, 1999, Interleukin-12 regulates the production of Bacille Calmette-Guerin-induced interferon-gamma from human cells in a CD40-dependent manner, Scand J Immunol, 50, 61
Luo, 1999, IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guerin immunotherapy, J Immunol, 162, 2399, 10.4049/jimmunol.162.4.2399
Chin, 1996, Mycobacterium cell wall: an alternative to intravesical bacillus Calmette Guerin (BCG) therapy in orthotopic murine bladder cancer, J Urol, 156, 1189, 10.1016/S0022-5347(01)65748-3
Kelley, 1985, Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results, J Urol, 134, 48, 10.1016/S0022-5347(17)46976-X
Shapiro, 1983, Reduction of bladder tumor growth in mice treated with intravesical bacillus Calmette-Guerin and its correlation with bacillus Calmette-Guerin viability and natural killer cell activity, Cancer Res, 43, 1611
Glashan, 1990, A randomized controlled study of intravesical α-2b-interferon in carcinoma in situ of the bladder, J Urol, 144, 658, 10.1016/S0022-5347(17)39547-2
Stricker, 1996, Bacillus Calmette-Guerin plus intravesical interferon alpha-2b in patients with superficial bladder cancer, Urology, 48, 957, 10.1016/S0090-4295(96)00375-5
Clinton, 2000, Interleukin-12. Opportunities for the treatment of bladder cancer, Urol Clin N Am, 27, 147, 10.1016/S0094-0143(05)70242-1
O'Donnell, 1994, Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes, Infect Immun, 62, 2508, 10.1128/IAI.62.6.2508-2514.1994